# Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

> **NCT04943224** · PHASE2 · RECRUITING · sponsor: **Anna Raciborska** · enrollment: 12 (estimated)

## Conditions studied

- Histiocytosis

## Interventions

- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT04943224
- **Lead sponsor:** Anna Raciborska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04943224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04943224, "Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04943224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*